Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5980/jpnjurol1928.75.12_1933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes.
Diabetes Technol Ther
January 2024
Insulet Corporation, Acton, Massachusetts, USA.
The Omnipod 5 Automated Insulin Delivery (AID) System was shown to be safe and effective following 3 months of use in people with type 1 diabetes (T1D); however, data on the durability of these results are limited. This study evaluated the long-term safety and effectiveness of Omnipod 5 use in people with T1D during up to 2 years of use. After a 3-month single-arm, multicenter, pivotal trial in children (6-13.
View Article and Find Full Text PDFModified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical Cystectomy and its Long-Term Clinical Outcomes.
Technol Cancer Res Treat
November 2023
Urology Department, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Objectives: This work aimed to prevent stoma stenosis and achieve tubeless cutaneous ureterostomy in elderly and high-risk patients with our modified cutaneous ureterostomy.
Methods: We retrospectively analyzed 40 and 49 patients (176 renal units) who underwent Toyoda (group 1) and modified cutaneous ureterostomy (group 2) between 2012 and 2021. The average follow-up period was 44 months.
Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial.
Diabetes Care
August 2022
Insulet Corporation, Acton, MA.
Objective: Very young children with type 1 diabetes often struggle to achieve glycemic targets, putting them at risk for long-term complications and creating an immense management burden for caregivers. We conducted the first evaluation of the Omnipod 5 Automated Insulin Delivery System in this population.
Research Design And Methods: A total of 80 children aged 2.
Introducing trifecta for percutaneous nephrolithotomies: a proposal for standard reporting outcomes after treatment for renal stones.
Minerva Urol Nephrol
June 2022
Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza, Italy.
Background: In literature, the reports of outcomes after percutaneous nephrolithotomies are rather heterogeneous. This may influence studies comparison, it may also render difficult to evaluate surgical adequacy, perioperative morbidity, and patient's Quality of Life between studies. For this reason, we propose to introduce PNL-Trifecta as composite measure to standardize data reporting outcomes after percutaneous nephrolithotomies.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes patients with diabetes using the tubeless Omnipod insulin pump, examining its effectiveness and the occurrence of acute complications over time.
- It included 3,657 patients, primarily with type 1 diabetes, and evaluated hemoglobin A1c levels and rates of diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) before and after starting the pump.
- Results showed a significant reduction in DKA and SH incidents after three years of therapy, indicating that tubeless insulin pump use is linked to improved glycemic control and high treatment retention rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!